Pharmaceutical Executive Daily: FDA's new Fast-Track Review

Oct 03, 07:47 PM

Headliner
Share
Subscribe

In today’s Pharmaceutical Executive Daily, we cover the FDA’s new fast-track review program for U.S.-made generics, Novartis’ FDA approval of Rhapsido for chronic spontaneous urticaria, and Halozyme’s $750 million acquisition of Elektrofi to strengthen drug delivery innovation.

Share
Subscribe
Next
Pharmaceutical Executive Daily: Updated Vaccine Recommendations
Top episodes
Healthcare Marketing Strategies for Reaching Diverse Audiences
by Pharmaceutical Executive
Tariffs and Drug Prices: Understanding the Impact on Pharmaceuticals
by Pharmaceutical Executive
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
by Pharmaceutical Executive